Drug intelligence / Profile preview

AFT-SP1

Development stage: Preclinical
Lead developer: AFT Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Subcutaneous

Overview

AFT-SP1 is a thermostable, fridge-free reformulation of an existing, undisclosed sterile injectable anti-infective drug. It is being developed by Stablepharma in partnership with AFT Pharmaceuticals using Stablepharma's proprietary StablevaX technology. This technology aims to stabilize biological and pharmaceutical products, eliminating the requirement for cold-chain storage and transport. AFT-SP1 is currently in the preclinical stage of development, with the specific active ingredient and target remaining confidential. The product is intended to provide a more accessible treatment option for infectious diseases, particularly in regions where maintaining a cold chain is challenging.

Beyond the preview

Go deeper on AFT-SP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFT-SP1.

Explore the full profile